Airfinity launches obesity intelligence solution to forecast and simulate obesity related outcomes

Posted on Jan 24, 2024

Today, Airfinity is launching an obesity intelligence solution to forecast and simulate obesity related outcomes The platform will provide insights on both the clinical and commercial landscapes, including pipeline, clinical trial activity, candidate progress tracker, benchmarking efficacy both in terms of weight loss and health benefits, approval predictions, supply and production, the private market and insurer coverage.  It will also examine scientific developments with tracking and analysis on disease prevalence and burden, cost effectiveness, downstream effects on comorbidity and other markets, real word evidence and adverse events.  Our models estimate the obesity drug market will generate sales of $80bn in the US alone by the end of the decade. It is a dynamic field with over 200 candidates in clinical development and an exponential increase in clinical trial activity.

Airfinity’s data solution and expert analysts will help clients navigate the evolving market through data simulations and predictive modelling.

Subscribers will get access to the platform and also receive real time alerts for key developments, a weekly newsletter summarising market updates and a biweekly in-depth report with high impact analyses. 

Airfinity Chief Medical Officer, Dr Henrik Sillesen, says, “Obesity drugs are a modern day gold rush for drugmakers. The success of GLP-1 receptor agonists is unlike other drugs because the pent up demand is driven by consumers.

“Normally medication is prescribed by doctors who think the patient needs treatment, obesity is different because people want to lose weight with the health benefits seen as an added bonus. 

“Currently the market is a two horse race with Novo Nordisk and Eli Lilly, but this is ripe to grow with enough demand for many more products”.

For more information please contact

More Insights From Airfinity

Introducing Airfinity Biorisk: Risk Surveillance and Analytics for 160+ Infectious Diseases

Oct 10, 2022

18 million monkeypox vaccines needed to protect most at risk, 85 million to protect wider gay community and health workers

Aug 25, 2022

Sales of COVID-19 antiviral pill Paxlovid to leap frog Merck’s competitor Molnupiravir

Jul 25, 2022

COVID-19 vaccines sales to bounce back with new jabs taking a fifth of the 2022 market

Jul 15, 2022

AstraZeneca and Pfizer/BioNTech saved over 12 million lives in the first year of vaccination

Jul 13, 2022

Global wastage of COVID-19 vaccines could be 1.1 billion doses

Jul 11, 2022